Trial Profile
A Phase 2, Prospective, Randomized, Open-Label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Defibrotide (Primary) ; Ciclosporin; Methotrexate; Mycophenolic acid; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals plc
- 04 Aug 2020 According to a Jazz Pharmaceuticals media release, the company expects to report top-line results from this study in late-2020.
- 14 May 2020 Status changed from active, no longer recruiting to completed.
- 29 Apr 2020 This trial has been completed in Belgium.